Unraveling the functional role of DNA demethylation at specific promoters by targeted steric blockage of DNA methyltransferase with CRISPR/dCas9.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
29 09 2021
Historique:
received: 31 03 2020
accepted: 07 09 2021
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

Despite four decades of research to support the association between DNA methylation and gene expression, the causality of this relationship remains unresolved. Here, we reaffirm that experimental confounds preclude resolution of this question with existing strategies, including recently developed CRISPR/dCas9 and TET-based epigenetic editors. Instead, we demonstrate a highly effective method using only nuclease-dead Cas9 and guide RNA to physically block DNA methylation at specific targets in the absence of a confounding flexibly-tethered enzyme, thereby enabling the examination of the role of DNA demethylation per se in living cells, with no evidence of off-target activity. Using this method, we probe a small number of inducible promoters and find the effect of DNA demethylation to be small, while demethylation of CpG-rich FMR1 produces larger changes in gene expression. This method could be used to reveal the extent and nature of the contribution of DNA methylation to gene regulation.

Identifiants

pubmed: 34588447
doi: 10.1038/s41467-021-25991-9
pii: 10.1038/s41467-021-25991-9
pmc: PMC8481236
doi:

Substances chimiques

FMR1 protein, human 0
Proto-Oncogene Proteins 0
RNA, Guide 0
SERPIN-B5 0
Serpins 0
Fragile X Mental Retardation Protein 139135-51-6
Mixed Function Oxygenases EC 1.-
TET1 protein, human EC 1.-
DNA Modification Methylases EC 2.1.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5711

Subventions

Organisme : CIHR
ID : PJT-159583
Pays : Canada

Informations de copyright

© 2021. The Author(s).

Références

Robertson, K. D. DNA methylation and human disease. Nat. Rev. Genet. 6, 597–610 (2005).
pubmed: 16136652 doi: 10.1038/nrg1655
Sutter, D. & Doerfler, W. Methylation of integrated adenovirus type 12 DNA sequences in transformed cells is inversely correlated with viral gene expression. Proc. Natl Acad. Sci. USA 77, 253–256 (1980).
pubmed: 6244548 pmcid: 348247 doi: 10.1073/pnas.77.1.253
Laird, P. W. & Jaenisch, R. The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 30, 441–464 (1996).
pubmed: 8982461 doi: 10.1146/annurev.genet.30.1.441
Labonte, B. et al. Genome-wide methylation changes in the brains of suicide completers. Am. J. Psychiatry 170, 511–520 (2013).
pubmed: 23511308 doi: 10.1176/appi.ajp.2012.12050627
Richardson, B. DNA methylation and autoimmune disease. Clin. Immunol. 109, 72–79 (2003).
pubmed: 14585278 doi: 10.1016/S1521-6616(03)00206-7
Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157–158 (2007).
pubmed: 17200673 doi: 10.1038/ng1941
Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39, 237–242 (2007).
pubmed: 17211412 pmcid: 2744394 doi: 10.1038/ng1972
Gal-Yam, E. N. et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl Acad. Sci. USA 105, 12979–12984 (2008).
pubmed: 18753622 pmcid: 2529074 doi: 10.1073/pnas.0806437105
Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232–236 (2007).
pubmed: 17200670 doi: 10.1038/ng1950
Pacis, A. et al. Gene activation precedes DNA demethylation in response to infection in human dendritic cells. Proc. Natl Acad. Sci. USA 116, 6938–6943 (2019).
pubmed: 30886108 pmcid: 6452747 doi: 10.1073/pnas.1814700116
Mutskov, V. & Felsenfeld, G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J. 23, 138–149 (2004).
pubmed: 14685282 doi: 10.1038/sj.emboj.7600013
Juttermann, R., Li, E. & Jaenisch, R. Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl Acad. Sci. USA 91, 11797–11801 (1994).
pubmed: 7527544 pmcid: 45322 doi: 10.1073/pnas.91.25.11797
Szyf, M. et al. Induction of myogenic differentiation by an expression vector encoding the DNA methyltransferase cDNA sequence in the antisense orientation. J. Biol. Chem. 267, 12831–12836 (1992).
pubmed: 1618783 doi: 10.1016/S0021-9258(18)42351-4
Robert, M. F. et al. Dnmt1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 33, 61–65 (2003).
pubmed: 12496760 doi: 10.1038/ng1068
Li, E., Bestor, T. H. & Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915–926 (1992).
pubmed: 1606615 doi: 10.1016/0092-8674(92)90611-F
Schmidt, T., Leha, A. & Salinas-Riester, G. Treatment of prostate cancer cells with S-adenosylmethionine leads to genome-wide alterations in transcription profiles. Gene 595, 161–167 (2016).
pubmed: 27688072 doi: 10.1016/j.gene.2016.09.032
He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307 (2011).
pubmed: 21817016 pmcid: 3462231 doi: 10.1126/science.1210944
Choudhury, S. R. et al. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncotarget 7, 46545–46556 (2016).
pubmed: 27356740 pmcid: 5216816 doi: 10.18632/oncotarget.10234
Xu, X. et al. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2, 16009 (2016).
pubmed: 27462456 pmcid: 4853773 doi: 10.1038/celldisc.2016.9
Morita, S. et al. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat. Biotechnol. 34, 1060–1065 (2016).
pubmed: 27571369 doi: 10.1038/nbt.3658
Frauer, C. et al. Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain. PLoS ONE 6, e21306 (2011).
pubmed: 21731699 pmcid: 3120858 doi: 10.1371/journal.pone.0021306
Hashimoto, H. et al. Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence. Genes Dev. 28, 2304–2313 (2014).
pubmed: 25258363 pmcid: 4201290 doi: 10.1101/gad.250746.114
Jin, S. G. et al. Tet3 reads 5-carboxylcytosine through its CXXC domain and is a potential guardian against neurodegeneration. Cell Rep. 14, 493–505 (2016).
pubmed: 26774490 pmcid: 4731272 doi: 10.1016/j.celrep.2015.12.044
Schneider, M. et al. Systematic analysis of the binding behaviour of UHRF1 towards different methyl- and carboxylcytosine modification patterns at CpG dyads. PLoS ONE 15, e0229144 (2020).
pubmed: 32084194 pmcid: 7034832 doi: 10.1371/journal.pone.0229144
Spruijt, C. G. et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152, 1146–1159 (2013).
pubmed: 23434322 doi: 10.1016/j.cell.2013.02.004
Wang, L. et al. Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature 523, 621–625 (2015).
pubmed: 26123024 pmcid: 4521995 doi: 10.1038/nature14482
Raiber, E. A. et al. 5-Formylcytosine alters the structure of the DNA double helix. Nat. Struct. Mol. Biol. 22, 44–49 (2015).
pubmed: 25504322 doi: 10.1038/nsmb.2936
Deplus, R. et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J. 32, 645–655 (2013).
pubmed: 23353889 pmcid: 3590984 doi: 10.1038/emboj.2012.357
Hrit, J. et al. OGT binds a conserved C-terminal domain of TET1 to regulate TET1 activity and function in development. Elife 7, e34870 (2018).
pubmed: 30325306 pmcid: 6214653 doi: 10.7554/eLife.34870
Liu, X. S. et al. Editing DNA methylation in the mammalian genome. Cell 167, 233–247 (2016).
pubmed: 27662091 pmcid: 5062609 doi: 10.1016/j.cell.2016.08.056
Polumuri, S. K. et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J. Immunol. 189, 50–60 (2012).
pubmed: 22634618 doi: 10.4049/jimmunol.1003554
Talabot-Ayer, D. et al. The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. J. Leukoc. Biol. 91, 119–125 (2012).
pubmed: 22013230 doi: 10.1189/jlb.0811425
Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).
pubmed: 23452860 pmcid: 3664290 doi: 10.1016/j.cell.2013.02.022
Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).
pubmed: 25494202 doi: 10.1038/nature14136
Ikeda, K., Stuehler, T. & Meisterernst, M. The H1 and H2 regions of the activation domain of herpes simplex virion protein 16 stimulate transcription through distinct molecular mechanisms. Genes Cells 7, 49–58 (2002).
pubmed: 11856373 doi: 10.1046/j.1356-9597.2001.00492.x
Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1911 (2018).
pubmed: 29765029 pmcid: 5953931 doi: 10.1038/s41467-018-04252-2
Klug, M. & Rehli, M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics 1, 127–130 (2006).
pubmed: 17965610 doi: 10.4161/epi.1.3.3327
Herman, J. G. et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525–4530 (1995).
pubmed: 7553621
Vilkaitis, G. et al. Processive methylation of hemimethylated CpG sites by mouse Dnmt1 DNA methyltransferase. J. Biol. Chem. 280, 64–72 (2005).
pubmed: 15509558 doi: 10.1074/jbc.M411126200
Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014).
pubmed: 24529477 pmcid: 4139937 doi: 10.1016/j.cell.2014.02.001
Zhu, X. et al. Cryo-EM structures reveal coordinated domain motions that govern DNA cleavage by Cas9. Nat. Struct. Mol. Biol. 26, 679–685 (2019).
pubmed: 31285607 pmcid: 6842131 doi: 10.1038/s41594-019-0258-2
Leonhardt, H. et al. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71, 865–873 (1992).
pubmed: 1423634 doi: 10.1016/0092-8674(92)90561-P
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
pubmed: 24157548 pmcid: 3969860 doi: 10.1038/nprot.2013.143
Jinek, M. et al. RNA-programmed genome editing in human cells. Elife 2, e00471 (2013).
pubmed: 23386978 pmcid: 3557905 doi: 10.7554/eLife.00471
Yoshioka, S. et al. Development of a mono-promoter-driven CRISPR/Cas9 system in mammalian cells. Sci. Rep. 5, 18341 (2015).
pubmed: 26669567 pmcid: 4680873 doi: 10.1038/srep18341
Fujii, W. et al. Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease. Nucleic Acids Res. 41, e187 (2013).
pubmed: 23997119 pmcid: 3814358 doi: 10.1093/nar/gkt772
Ren, X. et al. Enhanced specificity and efficiency of the CRISPR/Cas9 system with optimized sgRNA parameters in Drosophila. Cell Rep. 9, 1151–1162 (2014).
pubmed: 25437567 pmcid: 4250831 doi: 10.1016/j.celrep.2014.09.044
Yang, X. et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61, 7025–7029 (2001).
pubmed: 11585728
Sponheim, J. et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177, 2804–2815 (2010).
pubmed: 21037074 pmcid: 2993251 doi: 10.2353/ajpath.2010.100378
Aranyi, T. et al. Systemic epigenetic response to recombinant lentiviral vectors independent of proviral integration. Epigenet. Chromatin 9, 29 (2016).
doi: 10.1186/s13072-016-0077-1
Yamagata, Y. et al. Lentiviral transduction of CD34(+) cells induces genome-wide epigenetic modifications. PLoS ONE 7, e48943 (2012).
pubmed: 23145033 pmcid: 3492239 doi: 10.1371/journal.pone.0048943
Stemmer, M. et al. CCTop: an intuitive, flexible and reliable CRISPR/Cas9 target prediction tool. PLoS ONE 10, e0124633 (2015).
pubmed: 25909470 pmcid: 4409221 doi: 10.1371/journal.pone.0124633
Pliatsika, V. & Rigoutsos, I. “Off-Spotter”: very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR/Cas guide RNAs. Biol. Direct 10, 4 (2015).
pubmed: 25630343 pmcid: 4326336 doi: 10.1186/s13062-015-0035-z
Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014).
pubmed: 24463181 pmcid: 4016707 doi: 10.1093/bioinformatics/btu048
Wu, X. et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 32, 670–676 (2014).
pubmed: 24752079 pmcid: 4145672 doi: 10.1038/nbt.2889
Zhang, X.-H. et al. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol. Ther. Nucleic Acids 4, e264 (2015).
pubmed: 26575098 pmcid: 4877446 doi: 10.1038/mtna.2015.37
Tanasijevic, B. et al. Progressive accumulation of epigenetic heterogeneity during human ES cell culture. Epigenetics 4, 330–338 (2009).
pubmed: 19571681 doi: 10.4161/epi.4.5.9275
Bushman, F. et al. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3, 848–858 (2005).
pubmed: 16175173 doi: 10.1038/nrmicro1263
Lu, F. et al. Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev. 28, 2103–2119 (2014).
pubmed: 25223896 pmcid: 4180973 doi: 10.1101/gad.248005.114
Wiehle, L. et al. Tet1 and Tet2 protect DNA methylation canyons against hypermethylation. Mol. Cell. Biol. 36, 452–461 (2016).
pubmed: 26598602 pmcid: 4719427 doi: 10.1128/MCB.00587-15
Serandour, A. A. et al. Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res. 40, 8255–8265 (2012).
pubmed: 22730288 pmcid: 3458548 doi: 10.1093/nar/gks595
Charlton, J. et al. TETs compete with DNMT3 activity in pluripotent cells at thousands of methylated somatic enhancers. Nat. Genet. 52, 819–827 (2020).
pubmed: 32514123 pmcid: 7415576 doi: 10.1038/s41588-020-0639-9
Hon, G. C. et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol. Cell 56, 286–297 (2014).
pubmed: 25263596 pmcid: 4319980 doi: 10.1016/j.molcel.2014.08.026
Wang, L. et al. TET2 coactivates gene expression through demethylation of enhancers. Sci. Adv. 4, eaau6986 (2018).
pubmed: 30417100 pmcid: 6221537 doi: 10.1126/sciadv.aau6986
Lizio, M. et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 16, 22 (2015).
pubmed: 25723102 pmcid: 4310165 doi: 10.1186/s13059-014-0560-6
Zou, Z. et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263, 526–529 (1994).
pubmed: 8290962 doi: 10.1126/science.8290962
Seftor, R. E. et al. maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58, 5681–5685 (1998).
pubmed: 9865722
Zhang, M. et al. Maspin is an angiogenesis inhibitor. Nat. Med. 6, 196–199 (2000).
pubmed: 10655109 doi: 10.1038/72303
Sheng, S. et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl Acad. Sci. USA 93, 11669–11674 (1996).
pubmed: 8876194 pmcid: 38116 doi: 10.1073/pnas.93.21.11669
Beltran, A. et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26, 2791–2798 (2007).
pubmed: 17057734 doi: 10.1038/sj.onc.1210072
Futscher, B. W. et al. Role for DNA methylation in the control of cell type specific maspin expression. Nat. Genet. 31, 175–179 (2002).
pubmed: 12021783 doi: 10.1038/ng886
Sato, N. et al. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 23, 1531–1538 (2004).
pubmed: 14716296 doi: 10.1038/sj.onc.1207269
Domann, F. E. et al. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer 85, 805–810 (2000).
pubmed: 10709100 doi: 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
Wu, Y. et al. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer 10, 32 (2010).
pubmed: 20132554 pmcid: 2824712 doi: 10.1186/1471-2407-10-32
Wada, K. et al. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J. Invest. Dermatol. 122, 805–811 (2004).
pubmed: 15086568 doi: 10.1111/j.0022-202X.2004.22308.x
Tsytsykova, A. V. et al. Activation-dependent intrachromosomal interactions formed by the TNF gene promoter and two distal enhancers. Proc. Natl Acad. Sci. USA 104, 16850–16855 (2007).
pubmed: 17940009 pmcid: 2040403 doi: 10.1073/pnas.0708210104
O’Donnell, W. T. & Warren, S. T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25, 315–338 (2002).
pubmed: 12052912 doi: 10.1146/annurev.neuro.25.112701.142909
Coffee, B. et al. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22, 98–101 (1999).
pubmed: 10319871 doi: 10.1038/8807
Chiurazzi, P. et al. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet. 7, 109–113 (1998).
pubmed: 9384610 doi: 10.1093/hmg/7.1.109
Vershkov, D. et al. FMR1 reactivating treatments in fragile X iPSC-derived neural progenitors invitro and invivo. Cell Rep. 26, 2531–2539 (2019). e4.
pubmed: 30840878 doi: 10.1016/j.celrep.2019.02.026
Biacsi, R., Kumari, D. & Usdin, K. SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet. 4, e1000017 (2008).
pubmed: 18369442 pmcid: 2265469 doi: 10.1371/journal.pgen.1000017
Sheridan, S. D. et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLos ONE 6, e26203 (2011).
Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172, 979 (2018).
pubmed: 29456084 pmcid: 6375087 doi: 10.1016/j.cell.2018.01.012
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
pubmed: 24336571 doi: 10.1126/science.1247005
Allen, B. et al. Non-homologous end joining induced alterations in DNA methylation: a source of permanent epigenetic change. Oncotarget 8, 40359–40372 (2017).
pubmed: 28423717 pmcid: 5522286 doi: 10.18632/oncotarget.16122
Cheishvili, D. et al. DNA methylation controls unmethylated transcription start sites in the genome in trans. Epigenomics 9, 611–633 (2017).
pubmed: 28470094 doi: 10.2217/epi-2016-0141
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
doi: 10.1038/nature14248
Robertson, K. D. & Wolffe, A. P. DNA methylation in health and disease. Nat. Rev. Genet. 1, 11–19 (2000).
pubmed: 11262868 doi: 10.1038/35049533
Bergman, Y. & Cedar, H. DNA methylation dynamics in health and disease. Nat. Struct. Mol. Biol. 20, 274–281 (2013).
pubmed: 23463312 doi: 10.1038/nsmb.2518
Rountree, M. R. et al. DNA methylation, chromatin inheritance, and cancer. Oncogene 20, 3156–3165 (2001).
pubmed: 11420732 doi: 10.1038/sj.onc.1204339
Shames, D. S., Minna, J. D. & Gazdar, A. F. DNA methylation in health, disease, and cancer. Curr. Mol. Med. 7, 85–102 (2007).
pubmed: 17311535 doi: 10.2174/156652407779940413
Fuchikami, M. et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS ONE 6, e23881 (2011).
pubmed: 21912609 pmcid: 3166055 doi: 10.1371/journal.pone.0023881
Kordi-Tamandani, D. M., Sahranavard, R. & Torkamanzehi, A. DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia. Mol. Biol. Rep. 39, 10889–10893 (2012).
pubmed: 23065263 doi: 10.1007/s11033-012-1986-0
Kuratomi, G. et al. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol. Psychiatry 13, 429–441 (2008).
pubmed: 17471289 doi: 10.1038/sj.mp.4002001
van der Ploeg, L. H. & Flavell, R. A. DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues. Cell 19, 947–958 (1980).
pubmed: 6247075 doi: 10.1016/0092-8674(80)90086-0
Vardimon, L. et al. Methylation of adenovirus genes in transformed cells and in vitro: influence on the regulation of gene expression? Eur. J. Cell Biol. 25, 13–15 (1981).
pubmed: 6895196
Stein, R., Razin, A. & Cedar, H. In vitro methylation of the hamster adenine phosphoribosyltransferase gene inhibits its expression in mouse L cells. Proc. Natl Acad. Sci. USA 79, 3418–3422 (1982).
pubmed: 6954487 pmcid: 346431 doi: 10.1073/pnas.79.11.3418
Razin, A. & Szyf, M. DNA methylation patterns formation and functions. Biochim. Biophys. Acta 782, 331–342 (1984).
pubmed: 6383476 doi: 10.1016/0167-4781(84)90043-5
Walsh, C. P., Chaillet, J. R. & Bestor, T. H. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation [letter]. Nat. Genet. 20, 116–117 (1998).
pubmed: 9771701 doi: 10.1038/2413
Jones, P. A. Effects of 5-azacytidine and its 2’-deoxyderivative on cell differentiation and DNA methylation. Pharm. Ther. 28, 17–27 (1985).
doi: 10.1016/0163-7258(85)90080-4
Rountree, M. R., Bachman, K. E. & Baylin, S. B. Dnmt1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25, 269–277 (2000).
pubmed: 10888872 doi: 10.1038/77023
Fuks, F. et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24, 88–91 (2000).
pubmed: 10615135 doi: 10.1038/71750
Bai, S. et al. DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2. Mol. Cell Biol. 25, 751–766 (2005).
pubmed: 15632075 pmcid: 543426 doi: 10.1128/MCB.25.2.751-766.2005
Massart, R. et al. DNA methylation and transcription onset in the brain. Epigenomics 9, 797–809 (2017).
Suzuki, T. et al. A screening system to identify transcription factors that induce binding site-directed DNA demethylation. Epigenet. Chromatin 10, 60 (2017).
doi: 10.1186/s13072-017-0169-6
Kirillov, A. et al. A role for nuclear NF-kappaB in B-cell-specific demethylation of the Igkappa locus. Nat. Genet. 13, 435–441 (1996).
pubmed: 8696338 doi: 10.1038/ng0895-435
Mayran, A. & Drouin, J. Pioneer transcription factors shape the epigenetic landscape. J. Biol. Chem. 293, 13795–13804 (2018).
pubmed: 29507097 pmcid: 6130937 doi: 10.1074/jbc.R117.001232
Xu, X. et al. High-fidelity CRISPR/Cas9- based gene-specific hydroxymethylation rescues gene expression and attenuates renal fibrosis. Nat. Commun. 9, 3509 (2018).
pubmed: 30158531 pmcid: 6115451 doi: 10.1038/s41467-018-05766-5
Bachman, M. et al. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat. Chem. 6, 1049–1055 (2014).
pubmed: 25411882 pmcid: 4382525 doi: 10.1038/nchem.2064
Bachman, M. et al. 5-Formylcytosine can be a stable DNA modification in mammals. Nat. Chem. Biol. 11, 555–557 (2015).
pubmed: 26098680 pmcid: 5486442 doi: 10.1038/nchembio.1848
Pfaffeneder, T. et al. Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. Nat. Chem. Biol. 10, 574–581 (2014).
pubmed: 24838012 doi: 10.1038/nchembio.1532
Devesa-Guerra, I. et al. DNA methylation editing by CRISPR-guided excision of 5-methylcytosine. J. Mol. Biol. 432, 2204–2216 (2020).
Vella, P. et al. Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol. Cell 49, 645–656 (2013).
pubmed: 23352454 doi: 10.1016/j.molcel.2012.12.019
Chen, Q. et al. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493, 561–564 (2013).
pubmed: 23222540 doi: 10.1038/nature11742
Kaas, G. A. et al. TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron 79, 1086–1093 (2013).
pubmed: 24050399 doi: 10.1016/j.neuron.2013.08.032
Galonska, C. et al. Genome-wide tracking of dCas9-methyltransferase footprints. Nat. Commun. 9, 597 (2018).
pubmed: 29426832 pmcid: 5807365 doi: 10.1038/s41467-017-02708-5
Dixon, J. R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376–380 (2012).
pubmed: 22495300 pmcid: 3356448 doi: 10.1038/nature11082
Fang, S. et al. Tet inactivation disrupts YY1 binding and long-range chromatin interactions during embryonic heart development. Nat. Commun. 10, 4297 (2019).
pubmed: 31541101 pmcid: 6754421 doi: 10.1038/s41467-019-12325-z
Senner, C. E. et al. TET1 and 5-hydroxymethylation preserve the stem cell state of mouse trophoblast. Stem Cell Rep. 15, 1301–1316 (2020).
Maeder, M. L. et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 31, 1137–1142 (2013).
pubmed: 24108092 pmcid: 3858462 doi: 10.1038/nbt.2726
Hata, K. & Sakaki, Y. Identification of critical CpG sites for repression of L1 transcription by DNA methylation. Gene 189, 227–234 (1997).
pubmed: 9168132 doi: 10.1016/S0378-1119(96)00856-6
Cheishvili, D. et al. DNA methylation controls unmethylated transcription start sites in the genome in trans. Epigenomics 9, 611–633 (2017).
Lei, H. et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122, 3195–3205 (1996).
pubmed: 8898232 doi: 10.1242/dev.122.10.3195
Ficz, G. et al. FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell 13, 351–359 (2013).
pubmed: 23850245 pmcid: 3765959 doi: 10.1016/j.stem.2013.06.004
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
pubmed: 23287722 pmcid: 3712628 doi: 10.1126/science.1232033
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
pubmed: 25075903 pmcid: 4486245 doi: 10.1038/nmeth.3047
Li, L. C. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427–1431 (2002).
pubmed: 12424112 doi: 10.1093/bioinformatics/18.11.1427
Untergasser, A. et al. Primer3—new capabilities and interfaces. Nucleic Acids Res. 40, e115 (2012).
pubmed: 22730293 pmcid: 3424584 doi: 10.1093/nar/gks596
Krueger, F. Trim galore: a wrapper tool around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files. (2015).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
pubmed: 22388286 pmcid: 3322381 doi: 10.1038/nmeth.1923
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572 (2011).
pubmed: 21493656 pmcid: 3102221 doi: 10.1093/bioinformatics/btr167
Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
pubmed: 23034086 pmcid: 3491415 doi: 10.1186/gb-2012-13-10-r87
Turner, S. D. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. Journal of Open Source Software (2018).
Ho, D. W. H., Sze, K. M. F. & Ng, I. O. L. Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution with annotation capability. Oncotarget 6, 20959–20963 (2015).
pubmed: 26087185 pmcid: 4673242 doi: 10.18632/oncotarget.4187
Li, H. et al. The sequence alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Altschul, S. F. et al. Basic local alignment search tool. J. Mol. Biol. 215, 403–410 (1990).
pubmed: 2231712 doi: 10.1016/S0022-2836(05)80360-2
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
pubmed: 20110278 pmcid: 2832824 doi: 10.1093/bioinformatics/btq033

Auteurs

Daniel M Sapozhnikov (DM)

Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montreal, QC, Canada.

Moshe Szyf (M)

Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montreal, QC, Canada. moshe.szyf@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH